An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227)

Hellmann, Matthew; Ramalingam, Suresh; Reck, Martin; O'Byrne, Ken; Paz-Ares, Luis; Harbison, Christopher T; Bhagavatheeswaran, Prabhu; Nathan, Faith; Brahmer, Julie

doi:10.1186/2051-1426-3-S2-P154

Article metrics
Last updated: Thu, 25 Apr 2024 19:24:13 Z

An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227)

Access & Citations

2148

Article Accesses
0

Web of Science
8

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.